283 related articles for article (PubMed ID: 8803905)
21. [Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
Harten P
Med Klin (Munich); 2003 Jun; 98(6):344; author reply 344-5. PubMed ID: 12877108
[No Abstract] [Full Text] [Related]
22. Successful desensitization for hydroxychloroquine anaphylaxis.
Donado CD; Díez EM
J Rheumatol; 2010 Sep; 37(9):1975-6. PubMed ID: 20810530
[No Abstract] [Full Text] [Related]
23. Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al.
Wallace DJ
Arthritis Rheum; 2010 Sep; 62(9):2824; author reply 2824-5. PubMed ID: 20872599
[No Abstract] [Full Text] [Related]
24. [Long-term effects of hydroxychloroquine on metabolism of serum lipids and left ventricular structure and function in patients of systemic lupus erythematosus].
Meng J; Lu Y; Dong X; Liu H
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(13):965-8. PubMed ID: 24851679
[TBL] [Abstract][Full Text] [Related]
25. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
[TBL] [Abstract][Full Text] [Related]
26. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
Costedoat-Chalumeau N; Amoura Z; Hulot JS; Aymard G; Leroux G; Marra D; Lechat P; Piette JC
Ann Rheum Dis; 2007 Jun; 66(6):821-4. PubMed ID: 17324970
[TBL] [Abstract][Full Text] [Related]
27. Central variant of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: new associations?
Bag AK; Curé JK; Sullivan JC; Roberson GH
Lupus; 2010 Feb; 19(2):225-6. PubMed ID: 19880556
[No Abstract] [Full Text] [Related]
28. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ
Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565
[TBL] [Abstract][Full Text] [Related]
29. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
Yokogawa N; Kato Y; Sugii S; Inada S
Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
[TBL] [Abstract][Full Text] [Related]
30. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Costedoat-Chalumeau N; Amoura Z; Hulot JS; Hammoud HA; Aymard G; Cacoub P; Francès C; Wechsler B; Huong du LT; Ghillani P; Musset L; Lechat P; Piette JC
Arthritis Rheum; 2006 Oct; 54(10):3284-90. PubMed ID: 17009263
[TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).
Alarcón GS; McGwin G; Bertoli AM; Fessler BJ; Calvo-Alén J; Bastian HM; Vilá LM; Reveille JD;
Ann Rheum Dis; 2007 Sep; 66(9):1168-72. PubMed ID: 17389655
[TBL] [Abstract][Full Text] [Related]
32. Impending cardiac tamponade as the initial presentation of thymoma in a systemic lupus erythematosus patient.
Jang SJ; Wu YC; Chuang WY; Chung CM; Luo SF; Chu PH
Lupus; 2010 Mar; 19(3):337-40. PubMed ID: 20015914
[No Abstract] [Full Text] [Related]
33. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
Carmichael SJ; Day RO; Tett SE
Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
[TBL] [Abstract][Full Text] [Related]
34. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
35. Pneumocystis carinii pneumonia after discontinuation of hydroxychloroquine in 2 patients with systemic lupus erythematosus.
Podrebarac TA; Jovaisas A; Karsh J
J Rheumatol; 1996 Jan; 23(1):199-200. PubMed ID: 8838542
[No Abstract] [Full Text] [Related]
36. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
Fox RI; Dixon R; Guarrasi V; Krubel S
Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908
[TBL] [Abstract][Full Text] [Related]
37. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?
Costedoat-Chalumeau N; Leroux G; Piette JC; Amoura Z
Joint Bone Spine; 2010 Jan; 77(1):4-5. PubMed ID: 20022788
[No Abstract] [Full Text] [Related]
38. Hydroxychloroquine in lupus pregnancy.
Clowse ME; Magder L; Witter F; Petri M
Arthritis Rheum; 2006 Nov; 54(11):3640-7. PubMed ID: 17075810
[TBL] [Abstract][Full Text] [Related]
39. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.
Petri M
Curr Rheumatol Rep; 2011 Feb; 13(1):77-80. PubMed ID: 20978875
[TBL] [Abstract][Full Text] [Related]
40. Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease.
Tam LS; Li EK; Lam CW; Tomlinson B
Lupus; 2000; 9(6):413-6. PubMed ID: 10981644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
